ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
128.150,71
-0,10%
S&P 500
5.303,27
0,12%
US Dollar vs BRL
5,1047
-0,50%
Bitcoin
67.080,76
0,00%
Brent Oil
83,76
0,67%
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Pacira BioSciences Inc (PCRX)

  7. Pacira BioSciences Inc (PCRX) Notícias

PCRX

Pacira BioSciences (PCRX)

Pacira BioSciences Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:PCRX
DataHoraFonteTítuloCódigoCompanhia
14/05/202417:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PCRXPacira BioSciences Inc
10/05/202408:00GlobeNewswire Inc.Pacira BioSciences, Inc. Announces Pricing of $250.0 Million Aggregate Principal Amount of 2.125% Convertible Senior Notes due 2029NASDAQ:PCRXPacira BioSciences Inc
08/05/202417:05GlobeNewswire Inc.Pacira BioSciences, Inc. Announces Proposed Offering of $250.0 Million Aggregate Principal Amount of Convertible Senior NotesNASDAQ:PCRXPacira BioSciences Inc
07/05/202417:02Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PCRXPacira BioSciences Inc
07/05/202417:00GlobeNewswire Inc.Pacira BioSciences Reports First Quarter 2024 Financial Results and Announces $150 Million Share Repurchase programNASDAQ:PCRXPacira BioSciences Inc
07/05/202409:00GlobeNewswire Inc.Pacira BioSciences to Participate in Fireside Chat at the 2024 RBC Capital Markets Global Healthcare ConferenceNASDAQ:PCRXPacira BioSciences Inc
30/04/202409:00GlobeNewswire Inc.Pacira to Report First Quarter 2024 Financial Results on Tuesday May 7, 2024NASDAQ:PCRXPacira BioSciences Inc
02/04/202409:00GlobeNewswire Inc.Pacira BioSciences to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:PCRXPacira BioSciences Inc
13/03/202408:00GlobeNewswire Inc.Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the KneeNASDAQ:PCRXPacira BioSciences Inc
06/03/202410:00GlobeNewswire Inc.Pacira BioSciences to Participate in Fireside Chat at the Barclays 26th Annual Global Healthcare ConferenceNASDAQ:PCRXPacira BioSciences Inc
29/02/202417:33Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:PCRXPacira BioSciences Inc
29/02/202410:00GlobeNewswire Inc.Pacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial ResultsNASDAQ:PCRXPacira BioSciences Inc
22/02/202410:00GlobeNewswire Inc.Pacira to Report 2023 Financial Results on Thursday February 29, 2024NASDAQ:PCRXPacira BioSciences Inc
15/02/202410:36GlobeNewswire Inc.Pacira Announces Publication of Pivotal Study of EXPAREL as a Sciatic Nerve Block in the Popliteal Fossa for Patients After BunionectomyNASDAQ:PCRXPacira BioSciences Inc
07/02/202418:59Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PCRXPacira BioSciences Inc
07/02/202410:00GlobeNewswire Inc.Pacira BioSciences Awarded Brand Pharmaceuticals Agreement With Premier, Inc.NASDAQ:PCRXPacira BioSciences Inc
01/02/202412:45PR Newswire (US)G.O.A.T. Bowl I Registration Open to 4 Additional Pickleball TeamsNASDAQ:PCRXPacira BioSciences Inc
04/01/202419:18Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:PCRXPacira BioSciences Inc
04/01/202419:00GlobeNewswire Inc.Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2023 RevenuesNASDAQ:PCRXPacira BioSciences Inc
03/01/202410:00GlobeNewswire Inc.Pacira BioSciences to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:PCRXPacira BioSciences Inc
21/12/202309:30GlobeNewswire Inc.Pacira Appoints Frank D. Lee as Chief Executive OfficerNASDAQ:PCRXPacira BioSciences Inc
13/11/202311:41Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:PCRXPacira BioSciences Inc
10/11/202309:30GlobeNewswire Inc.Pacira Announces FDA Approval of Expanded EXPAREL Label to Include Two Additional Nerve Block IndicationsNASDAQ:PCRXPacira BioSciences Inc
07/11/202310:00GlobeNewswire Inc.Pacira BioSciences to Participate in Fireside Chat at Two Healthcare Conferences in NovemberNASDAQ:PCRXPacira BioSciences Inc
02/11/202309:00GlobeNewswire Inc.Pacira BioSciences Reports Third Quarter 2023 Financial ResultsNASDAQ:PCRXPacira BioSciences Inc
26/10/202309:00GlobeNewswire Inc.Pacira to Report Third Quarter 2023 Financial Results on Thursday November 2, 2023NASDAQ:PCRXPacira BioSciences Inc
12/10/202309:00GlobeNewswire Inc.American Society of Anesthesiologists Announces New Industry Supporter Pacira BioSciences, Inc.NASDAQ:PCRXPacira BioSciences Inc
10/10/202309:00GlobeNewswire Inc.Pacira BioSciences Appoints Four New Independent Directors to its Board of DirectorsNASDAQ:PCRXPacira BioSciences Inc
02/10/202309:00GlobeNewswire Inc.American Society of Anesthesiologists and Pacira BioSciences, Inc. Announce New Grant to Advance Education and Enhance Patient CareNASDAQ:PCRXPacira BioSciences Inc
26/09/202317:30GlobeNewswire Inc.Pacira BioSciences Announces Leadership Succession PlanNASDAQ:PCRXPacira BioSciences Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:PCRX

Seu Histórico Recente

BIT
F16756
Vontobel Financial Produ...
NASDAQ
MSFT
Microsoft
AMEX
MSL
Midsouth Bancorp
COIN
BERRYGBP
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados